{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:08:40Z","timestamp":1778486920573,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001787","name":"University of South Australia","doi-asserted-by":"crossref","award":["Summer Vacation Research Scholarship"],"award-info":[{"award-number":["Summer Vacation Research Scholarship"]}],"id":[{"id":"10.13039\/501100001787","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40264-025-01633-7","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T05:29:10Z","timestamp":1762234150000},"page":"655-665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A National Response to Warfarin Shortages: Evaluating Regulatory Substitution and Notified Shortages and Their Effects on Antithrombotic Dispensings, Pathology Monitoring and Adverse Event Trends in Australia"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8491-4886","authenticated-orcid":false,"given":"Roua","family":"Azroun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5063-6128","authenticated-orcid":false,"given":"Lisa Kalisch","family":"Ellett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8730-8910","authenticated-orcid":false,"given":"Nicole","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5121-5827","authenticated-orcid":false,"given":"Michael","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4171-3504","authenticated-orcid":false,"given":"Jack","family":"Janetzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"1633_CR1","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3389\/fphar.2019.00763","volume":"10","author":"A Acosta","year":"2019","unstructured":"Acosta A, Vanegas EP, Rovira J, Godman B, Bochenek T. Medicine shortages: gaps between countries and global perspectives. Front Pharmacol. 2019;10:763.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1633_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/1472-6963-14-438","volume":"14","author":"K Pauwels","year":"2014","unstructured":"Pauwels K, Huys I, Casteels M, Simoens S. Drug shortages in European countries: a trade-off between market attractiveness and cost containment? BMC Health Serv Res. 2014;14(1):438.","journal-title":"BMC Health Serv Res"},{"key":"1633_CR3","unstructured":"Australian Government Department of Health and Aged Care Therapeutic Goods Administration. Substitution instrument to address shortage of COUMADIN warfarin 5mg tablets. 2023 [cited 2025 11 February]. https:\/\/www.tga.gov.au\/safety\/shortages\/medicine-shortage-alerts\/substitution-instrument-address-shortage-coumadin-warfarin-5mg-tablets."},{"key":"1633_CR4","unstructured":"Wroth M. Warfarin shortage. 2023 [cited 2025 11 February]. https:\/\/www.agedcarequality.gov.au\/news-publications\/clinical-alerts\/warfarin-shortage."},{"key":"1633_CR5","unstructured":"Australian Government Department of Health and Aged Care Therapeutic Goods Administration. Warfarin shortages. 2023 [cited 2025 11 February]. https:\/\/www.tga.gov.au\/safety\/shortages\/medicine-shortage-alerts\/warfarin-shortages."},{"key":"1633_CR6","unstructured":"Australian Government Department of Health and Aged Care Therapeutic Goods Administration. Serious Scarcity Substitution Instruments (SSSIs). 2025 [cited 2025 11 June]. https:\/\/www.tga.gov.au\/safety\/shortages\/accessing-medicines-during-shortage\/serious-scarcity-substitution-instruments-sssis."},{"key":"1633_CR7","unstructured":"NHS Business Services Authority. Serious shortage protocols (SSPs). [cited 2025 11 June]. https:\/\/www.nhsbsa.nhs.uk\/pharmacies-gp-practices-and-appliance-contractors\/serious-shortage-protocols-ssps."},{"issue":"2","key":"1633_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.18773\/austprescr.2015.016","volume":"38","author":"PA Tideman","year":"2015","unstructured":"Tideman PA, Tirimacco R, St John A, Roberts GW. How to manage warfarin therapy. Aust Prescr. 2015;38(2):44\u20138.","journal-title":"Aust Prescr"},{"issue":"5","key":"1633_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.18773\/austprescr.2015.062","volume":"38","author":"L Graudins","year":"2015","unstructured":"Graudins L, Chen F, Hopper I. Warfarin brands. Aust Prescr. 2015;38(5):150\u20131.","journal-title":"Aust Prescr"},{"key":"1633_CR10","unstructured":"Australian Government Department of Health and Aged Care. Warfarin 2025 [cited 2025 11 February]. https:\/\/www.pbs.gov.au\/medicine\/item\/2843P."},{"issue":"2","key":"1633_CR11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1345\/aph.10207","volume":"35","author":"KA Hope","year":"2001","unstructured":"Hope KA, Havrda DE. Subtherapeutic INR values associated with a switch to generic warfarin. Ann Pharmacother. 2001;35(2):183\u20137.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"1633_CR12","first-page":"22","volume":"7","author":"F Chen","year":"2016","unstructured":"Chen F, Wang I, Graudins L, Hopper I. Is switching anticoagulant brands safe: Coumadin and Marevan? Austr Med Stud J. 2016;7(1):22\u20138.","journal-title":"Austr Med Stud J"},{"key":"1633_CR13","unstructured":"Australian Government Department of Health and Aged Care Therapeutic Goods Administration. Database of Adverse Event Notifications (DAEN). 2025 [cited 2025 January]. https:\/\/www.tga.gov.au\/safety\/database-adverse-event-notifications-daen"},{"key":"1633_CR14","first-page":"254","volume":"43","author":"D Brieger","year":"2014","unstructured":"Brieger D, Curnow J. Anticoagulation: a GP primer on the new oral anticoagulants. Austr J Gen Pract. 2014;43:254\u20139.","journal-title":"Austr J Gen Pract."},{"key":"1633_CR15","unstructured":"Pharmaceutical Benefit Scheme AG, Department of Health and Aged Care. PBS and RPBS Section 85 Date of Supply Data. 2024 [cited 2024 November]. https:\/\/www.pbs.gov.au\/info\/statistics\/dos-and-dop\/dos-and-dop."},{"issue":"4","key":"1633_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","volume":"27","author":"AK Wagner","year":"2002","unstructured":"Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299\u2013309.","journal-title":"J Clin Pharm Ther"},{"key":"1633_CR17","unstructured":"Australian Government Department of Health and Aged Care Therapeutic Goods Administration. Medicine shortage reports database. 2025."},{"key":"1633_CR18","unstructured":"Australia AGS. Medicare Benefits Schedule statistics. 2025 [cited 2025 January]. https:\/\/www.servicesaustralia.gov.au\/medicare-statistics?context=22."},{"issue":"1","key":"1633_CR19","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1186\/s13104-015-1616-8","volume":"8","author":"L Mellish","year":"2015","unstructured":"Mellish L, Karanges EA, Litchfield MJ, Schaffer AL, Blanch B, Daniels BJ, et al. The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers. BMC Res Notes. 2015;8(1):634.","journal-title":"BMC Res Notes"},{"issue":"5","key":"1633_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.18773\/austprescr.2024.045","volume":"47","author":"T Simpson","year":"2024","unstructured":"Simpson T, Yik J. Managing medicine shortages. Aust Prescr. 2024;47(5):148\u201352.","journal-title":"Aust Prescr"},{"key":"1633_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/jppr.1949","author":"JL Janetzki","year":"2024","unstructured":"Janetzki JL, Chai WC, Bui TNT, Sim TF, Suppiah V. Impact of medicine shortages on Australian pharmacists\u2019 professional practice and patient care: a nationwide survey. J Pharm Pract Res. 2024. https:\/\/doi.org\/10.1002\/jppr.1949.","journal-title":"J Pharm Pract Res"},{"issue":"1","key":"1633_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.18773\/austprescr.2020.077","volume":"44","author":"JH Martin","year":"2021","unstructured":"Martin JH, Lucas C. Reporting adverse drug events to the Therapeutic Goods Administration. Aust Prescr. 2021;44(1):2\u20133.","journal-title":"Aust Prescr"},{"issue":"5","key":"1633_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/14740338.2023.2224558","volume":"22","author":"AZ Al Meslamani","year":"2023","unstructured":"Al Meslamani AZ. underreporting of adverse drug events: a look into the extent, causes, and potential solutions. Expert Opin Drug Saf. 2023;22(5):351\u20134.","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"1633_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208824","volume":"13","author":"A Morgan","year":"2018","unstructured":"Morgan A, Joshy G, Schaffer A, Laba T-L, Litchfield M, Pearson S, et al. Rapid and substantial increases in anticoagulant use and expenditure in Australia following the introduction of new types of oral anticoagulants. PLoS ONE. 2018;13(12):e0208824.","journal-title":"PLoS ONE"},{"issue":"8","key":"1633_CR25","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.3390\/jcm14082591","volume":"14","author":"EJ Favaloro","year":"2025","unstructured":"Favaloro EJ, Pasalic L, Lippi G. Oral anticoagulation therapy: an update on usage and costs in the endemic COVID-19 era. J Clin Med. 2025;14(8):2591.","journal-title":"J Clin Med"},{"key":"1633_CR26","unstructured":"Health Design Lab. Understanding the impact of medicine shortages in Australia: Discovery report; 2024."},{"key":"1633_CR27","first-page":"12","volume":"2024","author":"N O'Donoghue","year":"2024","unstructured":"O\u2019Donoghue N. Pharmacists need regulators\u2019 trust for substitution. Austr J Pharm. 2024;2024:12.","journal-title":"Austr J Pharm"},{"issue":"1","key":"1633_CR28","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.sapharm.2020.05.033","volume":"17","author":"P Merks","year":"2021","unstructured":"Merks P, Jakubowska M, Drelich E, \u015awieczkowski D, Bogusz J, Bilmin K, et al. The legal extension of the role of pharmacists in light of the COVID-19 global pandemic. Res Soc Admin Pharm. 2021;17(1):1807\u201312.","journal-title":"Res Soc Admin Pharm"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01633-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01633-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01633-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T07:17:04Z","timestamp":1778483824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01633-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1633"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01633-7","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nicole Pratt is an Editorial Board member of Drug Safety. Nicole Pratt was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. RA was supported by a Summer Vacation Research Scholarship from Clinical and Health Sciences, University of South Australia. This research received no other specific grants from any funding agency in the public, commercial, or not-for-profit sectors. The funding source had no such involvement or restrictions regarding publication of this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethics approval was not required as all data used in this study are publicly available aggregate data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All authors were responsible for formulating the research questions, designing the study, and writing. RA and JJ conducted the study and analysed data. LKE, NP and MW reviewed manuscript drafts and all authors read and approved the final version.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"RA and JJ had complete access to the study data and ongoing access is provided publicly by Services Australia and the Therapeutic Goods Administration.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Access"}},{"value":"Data is freely and publicly accessible via the Database of Adverse Event Notifications (DAEN)\u2014medicines (\n                      \n                      ), The Pharmaceutical Benefits Scheme Section 85\u2014Date of Supply Data, Services Australia Medicare statistics (\n                      \n                      ) and the Therapeutic Goods Administration Medicine Shortages Database (\n                      \n                      ).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable. This study used publicly and freely available aggregate data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable. This study does not contain individual-level data.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Code, including that for the interrupted time series analysis, is available on reasonable request from the corresponding author.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}